Ataxion

Ataxion is a discovery-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for rare and underserved neurologic diseases. Founded in April 2013 by Dr. Josh Resnick and David Grayzel, MD, through the Atlas Venture seed program, Ataxion specializes in small-molecule therapeutics that target hereditary ataxia and other degenerative neurological disorders such as multiple sclerosis and Huntington's disease. By leveraging ion-channel modulators, the company aims to provide effective treatments for patients suffering from these debilitating conditions.